Alembic Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of entacapone as an add-on therapy for treating end-of-dose “wearing off” in Parkinson’s disease, the company announced. These entacapone tablets are “therapeutically equivalent” to Comtan and treat the motor…

The use of several Parkinson’s disease medications was significantly associated with the increased abundance of a bacterial enzyme that converts levodopa to dopamine in the gut, potentially reducing levodopa’s availability in the brain, a study found. In Parkinson’s patients with rapidly progressing disease, the approved therapy Comtan (entacapone)…

Oral Ongentys (opicapone) as a daily add-on treatment shortened overnight “off” periods and eased dyskinesia during “on” periods in people with Parkinson’s disease using levodopa, new analyses of Phase 3 clinical trial data show. Long-term use was also seen to lower patients’ average daily levodopa dose without worsening symptoms…

A review by the U.S. Food and Drug Administration (FDA) found that Parkinson’s patients treated with medications containing entacapone are at no increased risk of prostate cancer. As such, the agency stands by its current recommendations for the use of Stalevo (entacapone/carbidopa/levodopa) and Comtan (entacapone; brand name is Comtess…

Once-daily opicapone can prolong the time during which treatment with levopoda, a standard therapy, effectively prevents motor symptom fluctuations in people with Parkinson’s disease, results from two international Phase 3 studies show. The findings, “Once-Daily Opicapone Increases ON-Time in Patients with Parkinson’s Disease: Results from Two Phase…

Treatment with Xadago (safinamide) or cannabinoids and opioids may the best therapeutic options to effectively manage pain in patients with Parkinson’s disease, researchers suggest. The study, “Comprehensive Examination of Therapies for Pain in Parkinson’s Disease: A Systematic Review and Meta-Analysis,” was published in the journal…

Once-daily treatment with opicapone provides continued reductions of off periods in Parkinson’s patients taking levodopa, a Phase 3 clinical study shows. The findings also reveal that opicapone’s effectiveness was superior to that of Comtan (entacapone, marketed by Novartis). The results were presented in three scientific posters at the 2018 World…